Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference48 articles.
1. Cell signaling by receptor tyrosine kinases;Schlessinger;Cell,2000
2. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005
3. Untangling the ErbB signaling network;Yarden;Nat Rev Mol Cell Biol,2001
4. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients;Tang;Cancer Res,2005
5. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers;Herbst;Semin Oncol,2002
Cited by 69 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12
2. The History and Development of HER2 Inhibitors;Pharmaceuticals;2023-10-12
3. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4);Journal of Thoracic Oncology;2023-08
4. Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?;Journal of Thoracic Oncology;2023-08
5. Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies;Thoracic Cancer;2023-04-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3